Britain and America have signed a key commercial pact that will ensure no levies on British drug shipments going into the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase spending on medicines through the NHS. This move ensures that import taxes on these key goods will be held at zero for a timeframe of the next three years.
This development is in response to recent threats to hike import taxes on branded pharmaceutical products, with figures floated reaching 100%.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and introduces much-needed fairness to U.S.–U.K. drug exports," an announcement said.
Economic Importance
Drugs represent one of the Britain's largest export categories to the America, which is by far the largest market for major UK drugmakers.
Statistics reveal that in the one-year period to the end of last September, the UK exported drugs totaling billions to the US. This value accounted for a significant portion of British export trade in that timeframe.
"This deal secures employment, increases funding and sets the stage for the UK to establish itself as a worldwide center for biotech and pharma," a minister commented.
Key UK Commitments
The agreement includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new therapies to be unaffordable by a quarter.
- Higher Drug Budget: There is a target to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must return to the NHS to control costs will be restricted at fifteen percent. Previously, repayments topped twenty percent.
Broader Context
The pact comes amid a ongoing dispute between the sector and the British authorities over spending levels and approval rates.
The disagreement were intensified by claims that US customers were paying several times more for the identical medicines than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or scrapped, while substantial expansions have been announced toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the past decade.
